EU Omnibus VIII Landed May 1 With No Sell-Through — Silver, CMRs, and Hexyl Salicylate Are Now Live Compliance Risk

EU Regulation (EU) 2026/78 — the eighth Omnibus update to Regulation (EC) No. 1223/2009 — became enforceable on May 1, 2026, with no sell-through period for existing inventory. The regulation bans perboric acid, silver and carbon nanotubes, and newly classified CMR (carcinogenic, mutagenic, or reproductive toxin) compounds including acetone oxime. Silver powder (CI 77820) is now permitted only in lip and eye products at ≤0.2%; hexyl salicylate is restricted to a maximum 2% in hydroalcoholic fragrances. Any non-compliant product already on shelf must be removed immediately.

The "no sell-through" clause is the operative clause most brands appear not to have fully priced in. Unlike previous Omnibus iterations that allowed brands to exhaust existing inventory, Omnibus VIII requires immediate market removal — meaning retailers with non-compliant SKUs from clean and natural brands that use silver-derived actives or hexyl salicylate-heavy fragrance accords now face compliance liability. This is not a future deadline; it is active now.

Brands marketing "colloidal silver" cosmetics in the EU — a trend that picked up in the natural space post-2020 — have a specific, immediate problem. This also matters for any brand using "nano" positioning as a delivery mechanism in the EU market: the nano-silver ban under Annex II has no carve-outs for cosmetic applications. This is a separate compliance instrument from the fragrance allergen rule already covered in our May 17 brief — same Omnibus number, distinct ingredient surface. Treat them as parallel workstreams, not one.